Paranta Biosciences is seeking expressions of interest from drug development and pharmaceutical companies to partner in the development of follistatin therapies for the following conditions:

•     Idiopathic Pulmonary Fibrosis (IPF)
•     Cystic Fibrosis (CF)
•     Chronic Obstructive Pulmonary Disease (COPD)
•     Chronic Bronchitis
•     Influenza
•     Asthma
•     Liver Fibrosis / Cirrhosis
•     Sepsis / Septicemia
•     Cachexia
•     Organ Transplant

For further information on partnering, collaboration and licensing opportunities, please contact the company’s CEO on:

T +61 (3) 9208 4176
E contact@parantabio.com